Breast Cancer Prevention Trial shows major benefit, some risk.
Smigel
K
K
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000517:prevention & control*; D003327:Coronary Disease / Q000517:prevention & control; D004965:Estrogen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D015994:Incidence; D009316:National Institutes of Health (U.S.); D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States
D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D013629:Tamoxifen